Cell Medica develops, manufactures and commercialises patient-specific cellular immunotherapy products comprised of antigen-specific T cells for the treatment of infectious disease and cancer. Founded in 2006, Cell Medica has developed a proprietary approach (patents filed) to the GMP manufacture of cell products and employs a team of production specialists led by Rainer Knaus, PhD and Katy Newton, PhD. The in-house trial management team, led by Karen Hodgkin, has unique expertise in planning and executing cell therapy trials.
Cell Medica has developed cell therapies for specific viral infections following bone marrow (haematopoietic stem cell) transplant, a procedure often undertaken for people with leukaemia and other haematological malignancies. The company is currently sponsoring two trials addressing the treatment of cytomegalovirus (CMV) infections and will launch a third study in 2012 to investigate the treatment of adenovirus (ADV) infections.
In cancer, we are targeting malignancies associated with the oncogenic Epstein Barr virus (EBV). Our treatment involves using immune cells to recognise and kill malignant cells expressing EBV antigens. Cell Medica is developing this cell therapy in collaboration with the Center for Cell and Gene Therapy at Baylor College of Medicine (CAGT).